NASDAQ
67.82USD
+0.71 (+1.06%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.2B
P/E
—
EPS
—
Beta
0.10
52W range
9.63-72.64
Day range
65.25–70.00
Open
69.69
Prev close
67.11
Volume
545.5K
Avg volume
834.2K
Dividend
0.00
IPO
2024-09-13
https://www.globenewswire.com/news-release/2026/07/13/3326463/0/en/MBX-Biosciences-Announces-Executive-Leadership-Transition-to-Support-the-Company-s-Next-Phase-of-Growth.html · 7/13/2026+0.00
https://seekingalpha.com/article/4914571-mbx-biosciences-inc-mbx-discusses-one-year-data-from-phase-ii-open-label-extension-study-of · 6/12/2026+0.60
https://www.defenseworld.net/2026/04/04/critical-analysis-immune-therapeutics-otcmktsimun-mbx-biosciences-nasdaqmbx.html · 4/4/2026+0.80
https://www.globenewswire.com/news-release/2026/04/03/3267994/0/en/MBX-Biosciences-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html · 4/3/2026+0.20
https://www.globenewswire.com/news-release/2026/03/09/3251975/0/en/CORRECTING-REPLACING-MBX-Biosciences-Announces-Successful-End-of-Phase-2-FDA-Meeting-and-Provides-Phase-3-Development-Plan-for-Once-Weekly-Canvuparatide-for-Hypoparathyroidism.html · 3/9/2026+0.80
https://www.defenseworld.net/2026/01/10/microbix-biosystems-tsembx-shares-cross-below-50-day-moving-average-should-you-sell.html · 1/10/2026-0.20
https://www.defenseworld.net/2025/12/25/mbx-biosciences-nasdaqmbx-reaches-new-12-month-high-still-a-buy.html · 12/25/2025+0.80
https://www.globenewswire.com/news-release/2025/12/15/3205354/0/en/MBX-Biosciences-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference-on-January-13.html · 12/15/2025+0.20
https://www.globenewswire.com/news-release/2025/09/25/3155944/0/en/MBX-Biosciences-Announces-Pricing-of-Upsized-Public-Offering.html · 9/25/2025+0.40
https://www.globenewswire.com/news-release/2025/09/22/3154306/0/en/MBX-Biosciences-Announces-Proposed-Public-Offering.html · 9/22/2025-0.20
https://www.globenewswire.com/news-release/2025/09/03/3143958/0/en/Microbix-Hosts-Ontario-Minister-Stephen-Crawford.html · 9/3/2025+0.80
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
